Articles

Gilead's Hepcludex Secures FDA Approval: Implications for Pharma

Gilead Sciences' Hepcludex has received FDA approval for hepatitis D, marking a significant milestone after previous manufacturing setbacks. This article explores the implications for the pharmaceutical industry.

Ebola Outbreak Worsens: Implications for Women and Girls

The ongoing Ebola outbreak poses significant risks, particularly for women and girls. This article explores the implications for the pharmaceutical industry.

Stay Informed: Five Key Biotech Updates from STAT+

Stay ahead in the biotech landscape with these five crucial updates from STAT+. Understand their implications for your business strategy.

Acadia Pharmaceuticals Enhances Parkinson's Campaign with Ryan Reynolds

Acadia Pharmaceuticals has launched an enhanced campaign for Parkinson's disease featuring Ryan Reynolds. This article explores the implications for the pharmaceutical sector.

Eli Lilly's New Gene Therapy and Strategic Deals: Insights for Investors

Eli Lilly is making headlines with a new gene therapy for cholesterol and several strategic deals. This article breaks down the implications for business development teams and investors.

Astellas Cuts Costs Amid FDA Review of Moderna Vaccine

Astellas Pharma is implementing cost reductions as the FDA panel prepares to review the Moderna vaccine. This article explores the implications for the pharmaceutical industry.

Trump's Annual Physical: Implications for Pharma Stakeholders

As Trump undergoes his annual physical, the implications for the pharmaceutical industry are significant. This article explores what pharma teams should consider.

SK bioscience's $260M Deal for Varicella Vaccine Production in Colombia

SK bioscience has secured a $260M deal to manufacture varicella vaccines in Colombia, marking a significant investment in local production. This move has important implications for the pharmaceutical landscape in Latin America.

Eli Lilly's Billion-Dollar Bet on Verve: Early Heart Drug Data

Eli Lilly's early data on the heart drug Verve underscores its significant investment potential. This article explores the implications for pharma teams and investors.

Lilly Expands Vaccine Research with Strategic Biotech Acquisitions

Eli Lilly has made significant strides in vaccine research through three strategic biotech acquisitions. This article explores the implications for the pharmaceutical industry.

Understanding the Financial Implications of STAT+: $775 Billion, $1.2 Billion, and $38K

This article delves into the financial figures reported by STAT+ and their implications for the pharmaceutical industry, providing insights for B2B readers.

Lantheus Considers $7B Acquisition of Curium: Implications for Pharma

Lantheus is contemplating a significant acquisition of Curium Pharma, which could reshape the radiopharmaceutical landscape. This article explores the implications for the industry.

Impact of COINS Act Expansion on China Biotech Licensing

The expansion of the COINS Act raises questions about its effects on China biotech licensing. This article explores the implications for BD teams and investors.

Praise for FDA’s Acting Commissioner: Implications for Pharma

This article examines the recent praise for the FDA's acting commissioner and its implications for the pharmaceutical sector. Key insights for business leaders and investors are provided.

Mirum Maps FDA Path After Anti-Itch Candidate Scores Phase 2 Win

Mirum's recent Phase 2 trial success for its anti-itch candidate marks a significant step towards FDA approval, impacting oncology strategies. This analysis explores the implications for investors and pharma teams.

The Innovation Trap: How Pharma Extends Monopolies

This article delves into the strategic use of the term 'innovation' by pharmaceutical companies to maintain monopolies and its implications for the industry.

How China is Reshaping Biotech Venture Financing

Simeon George of SR One discusses the transformative impact of China on biotech venture financing, highlighting key trends and implications for the industry.

AI Drug Development: Insights from a Biotech CEO

This article delves into the insights shared by a biotech CEO regarding the realities of AI in drug development, addressing common misconceptions and implications for the industry.

Kyle Diamantas: Rising to Lead the FDA Against All Odds

Kyle Diamantas' unexpected rise to lead the FDA marks a pivotal moment for the pharmaceutical industry. This article explores the implications of his leadership.

Targeted Protein Degraders: A New Era in Cancer Treatment

This article examines the potential of targeted protein degraders in cancer therapy, focusing on KRAS elimination and its implications for the pharmaceutical industry.